JCOGP
Journal of Controversies in Obstetrics & Gynecology and Pediatrics

As of January 2023, our "Journal of Controversies Obstetrics & Gynecology and Pediatrics" has been published under the Medihealth Academy to publish all articles, reviews and case reports on Pediatrics, especially in the field of Obstetrics and Gynecology. In order to facilitate the citation of the articles, to take our place in internationally respected indexes and to reach a wider readership, we will pay attention to the fact that our article language is only English in terms of acceptance. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

eISSN: 2980-0579
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Effects of long-term high-dose medroxyprogesterone acetate use on bone mineral density in postmenopausal women
Abstract
Aims: The aim of this study was to investigate the relationship between long-term depot medroxyprogesterone acetate (DMPA) use and bone mineral density (BMD) in postmenopausal women.
Methods: This study was conducted on 40 postmenopausal women who presented at the SSK Okmeydanı Training and Research Hospital Gynecology and Obstetrics Polyclinic. The sample for the study was randomly selected from postmenopausal women and divided into the control group (N=20) and the medroxyprogesterone acetate group (N=19).
Results: A total of 39 participants were included in this study, 19 cases and 20 controls. Long-term DMPA users had higher BMD compared with the control group. These differences from the control group were statistically and potentially clinically significant. The BMD in the control group has decreased significantly during one year of study. Based on the results, the longterm use of DMPA significantly affects the bone mineral density in postmenopausal women, increasing BMD.
Conclusion: Long-term use of DMPA was associated with improved BMD after treatment. The findings demonstrate the need for long-term, controlled, prospective studies with adequate sample size to evaluate the potential clinical impact of DMPA use on bone health outcomes in postmenopausal women.

Keywords : Depot medroxyprogesterone acetate, bone mineral density, osteoporosis, postmenopause, women

Download Article


1. Rostami-Moez M, Masoumi SZ, Otogara M, Farahani F, Alimohammadi S, Oshvandi K. Examining the health-related needs of females during menopause: a systematic review study.<em>J Menopausal Med</em>. 2023;29(1):1-20. doi:10.6118/jmm.22033
2. Uzun S, Ozcan H, Jones D. The psychological dimension of menopause: a phenomenological study: being menopause in Turkiye: a qualitative study. <em>Curr Psychol. </em>2023;42(13):10498-507.
3. Habeeb S. Menopause: transition, effects, and methods. in: encyclopedia of sexual psychology and behavior. <em>Springer</em>. 2023. p. 1-12. Zhang S, Huang X, Zhao X, et al. Effect of exercise on bone mineral density among patients with osteoporosis and osteopenia: a systematic review and network meta-analysis.<em>J Clin Nurs</em>. 2022;31(15-16):2100-2111. doi:10.1111/jocn.16101
4. Zhang S, Huang X, Zhao X, et al. Effect of exercise on bone mineraldensity among patients with osteoporosis and osteopenia: a systematicreview and network meta-analysis.J Clin Nurs. 2022;31(15-16):2100-2111.doi:10.1111/jocn.16101
5. Watts NB, Binkley N, Owens CD, et al. Bone mineral density changes associated with pregnancy, lactation, and medical treatments in premenopausal women and effects later in life.<em>J Womens Health (Larchmt)</em>. 2021;30(10):1416-1430. doi:10.1089/jwh.2020.8989
6. Kolodziejska B, Stepien N, Kolmas J. The influence of strontium on bone tissue metabolism and its application in osteoporosis treatment.<em>Int J Mol Sci</em>. 2021;22(12):6564. doi:10.3390/ijms22126564
7. Bonnick SL. Osteoporosis in men and women.<em>Clin Cornerstone</em>. 2006;8(1):28-39. doi:10.1016/s1098-3597(06)80063-3
8. S&ouml;zen T, &Ouml;zışık L, Başaran N&Ccedil;. An overview and management of osteoporosis.<em>Eur J Rheumatol</em>. 2017;4(1):46-56. doi:10.5152/eurjrheum. 2016.048
9. Dimai HP, Fahrleitner-Pammer A. Osteoporosis and fragility fractures: currently available pharmacological options and future directions.<em>Best Pract Res Clin Rheumatol</em>. 2022;36(3):101780. doi:10.1016/j.berh.2022.101780
10. Dempster DW. Osteoporosis and the burden of osteoporosis-related fractures.<em>Am J Manag Care</em>. 2011;17 (Suppl 6):S164-S169.
11. Tuzun S, Eskiyurt N, Akarirmak U, et al. Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study.<em>Osteoporos Int</em>. 2012;23(3):949-955. doi:10.1007/s00198-011-1655-5
12. Keskin Y, Cekin Md, G&uuml;nd&uuml;z H, et al. The prevalence of osteoporosis in the thrace region of Turkey: a community-based study. <em>Turk J Phys Med Rehabil Fiz Tip Ve Rehabil Derg</em>. 2014;60(4):335-340
13. Rajaraman R, Vaithilingan S, Selvavinayagam TS. Acceptance, adherence, and side effects of depot medroxyprogesterone acetate: a prospective observational study.<em>Cureus</em>. 2024;16(4):e58700. doi:10.7759/cureus.58700
14. Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.<em>Contraception</em>. 2008;77(2):67-76. doi:10.1016/j.contraception.2007.10.005
15. Roksvaag I, Skjeldestad FE. Decreasing trends in number of depot medroxyprogesterone acetate starters in Norway - a cross-sectional study. <em>Acta Obstet Gynecol Scand</em>. 2018;97(2):151-157. doi:10.1111/aogs. 13262
16. Kaunitz AM. Depot medroxyprogesterone acetate (DMPA): efficacy, side effects, metabolic impact, and benefits. UpToDate Accessed March 23 2023 Dispon En Httpswww Uptodate Comcontentsdepot-Medroxyprogesteroneacetate-Dmpa-Effic-Side-Eff-Metab-Impact--<em>Benefits</em>. 2022;
17. Clark MK, Sowers MR, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate.<em>Fertil Steril</em>. 2004;82(6):1580-1586. doi:10.1016/j.fertnstert.2004.04.064
18. Harel Z, Johnson CC, Gold MA, et al. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections.<em>Contraception</em>. 2010;81(4):281-291. doi:10.1016/j.contraception.2009.11.003
19. Beksinska ME. Bone mineral density and use of depot medroxyprogesterone acetate (DMPA), norethisterone enanthate (NET-EN) and combined oral contraceptives. 2010;
20. Scholes D, Lacroix AZ, Ott SM, Ichikawa LE, Barlow WE. Bone mineral density in women using depot medroxyprogesterone acetate for contraception.<em>Obstet Gynecol</em>. 1999;93(2):233-238. doi:10.1016/s0029-7844(98)00447-5
21. Ebeisy HAEHE, Mahmoud NE, Kandeel HT, Tawwab SMSE. Bone mineral density among long term users of hormonal contraception (Contraception &amp; Bone mineral density). <em>Al-Azhar Int Med J. </em>2024;5(2):25.
22. Cheng CH, Chen LR, Chen KH. Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover.<em>Int J Mol Sci</em>. 2022;23(3):1376. doi:10.3390/ijms 23031376.
23. Rajan R, Paul J, Kapoor N, Cherian KE, Paul TV. Postmenopausal osteoporosis-an Indian perspective. <em>Curr Med Issues</em>. 2020;18(2):98-104.
24. Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen.<em>Am J Med</em>. 1991; 90(2):171-178.
25. Viola AS, Castro S, Marchi NM, Bahamondes MV, Viola CF, Bahamondes L. Long-term assessment of forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate.<em>Contraception</em>. 2011;84(2):122-127. doi:10.1016/j.contraception.2010.11.007
26. Viola AS, Castro S, Bahamondes MV, Fernandes A, Viola CF, Bahamondes L. A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate. <em>Contraception</em>. 2011;84(5):e31-e37. doi:10. 1016/j.contraception.2011.06.012
27. Sanches L, Marchi NM, Castro S, Juliato CT, Villarroel M, Bahamondes L. Forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate [published correction appears in Contraception. 2009 79(2):159-60].<em>Contraception</em>. 2008;78(5):365-369. doi:10.1016/j.contraception.2008.07.013
28. Modesto W, Bahamondes MV, Bahamondes L. Prevalence of low bone mass and osteoporosis in long-term users of the injectable contraceptive depot medroxyprogesterone acetate.<em>J Womens Health (Larchmt)</em>. 2015;24(8):636-640. doi:10.1089/jwh.2014.5077
Article available in :
Volume 2, Issue 4, 2024
Page : 78-82
https://doi.org/10.51271/JCOGP-0035
Article Information
Received : 04 Eyl 2024
Accepted : 01 Eki 2024
Published : 23 Eki 2024
Corresponding Author :

Altuğ Semiz: Department of Obstetrics and Gynecology, Faculty of Medicine, İstinye University, İstanbul, Turkiye

[email protected]
Citation : Semiz A. Effects of long-term high-dose medroxyprogesterone acetate use on bone mineral density in postmenopausal women. J Controv Obstetr Gynecol Ped. 2024;2(4):78-82.

Read: 57
Cited: 0
Download : 26
_Footer